All In Biotech

Drug Trial Radar · NCT01712490

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,334 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,334

Actual

Start

Nov 9, 2012

Primary completion

Apr 20, 2017

Study completion Feb 2, 2026

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
Seagen Inc.
First posted
Oct 23, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin \[Adriamycin\], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin \[Adriamycin\],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)

Conditions

  • Hodgkin Lymphoma

Interventions

  • brentuximab vedotinDrug

    Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.

  • doxorubicinDrug

    Doxorubicin: 25 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

  • bleomycinDrug

    Bleomycin: 10 units/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

  • vinblastineDrug

    Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

  • dacarbazineDrug

    Dacarbazine (DTIC): 375 mg/m\^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF)Time frame: Baseline until PD or death or receipt of any subsequent anticancer therapy for HL after completion of frontline therapy (approximately up to 4 years)

Locations

215 sites in 21 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Gilbert, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Burbank, California

  • Site not named

    Duarte, California

  • Site not named

    Fresno, California

  • Site not named

    Fullerton, California

  • Site not named

    La Jolla, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    San Luis Obispo, California

  • Site not named

    Santa Barbara, California

  • Site not named

    Santa Monica, California

  • Site not named

    Stanford, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Lonetree, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Fort Myers, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Lawrenceville, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Maywood, Illinois

  • Site not named

    Niles, Illinois

  • Site not named

    Zion, Illinois

  • Site not named

    Fort Wayne, Indiana

  • Site not named

    Goshen, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    Fairway, Kansas

  • Site not named

    Baltimore, Maryland

  • Site not named

    Bethesda, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Rochester, Minnesota

Showing 40 of 215 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.